Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer

Int J Oncol. 1998 Dec;13(6):1235-40. doi: 10.3892/ijo.13.6.1235.


We examined the effect of Tranilast on the reduction of the administered dose of cisplatin using a scirrhous gastric cancer model. Scirrhous gastric cancer cell line, OCUM-2M, and gastric fibroblasts, NF-10, were used. The IC50 values of CDDP to OCUM-2M cells were decreased by Tranilast in vitro. The combination treatment with Tranilast and CDDP decreased the xenografted tumor size. The combination therapy decreased fibrosis and mitosis, and increased apoptosis. These findings suggest that Tranilast increased the CDDP response on scirrhous gastric cancer. The combination treatment with Tranilast and CDDP may be useful as a new therapy for scirrhous gastric carcinoma.

MeSH terms

  • Adenocarcinoma, Scirrhous / drug therapy*
  • Adenocarcinoma, Scirrhous / pathology
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cell Division / drug effects
  • Cisplatin / administration & dosage
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Transplantation, Heterologous
  • Tumor Cells, Cultured
  • ortho-Aminobenzoates / administration & dosage


  • ortho-Aminobenzoates
  • tranilast
  • Cisplatin